• EE436 General-Purpose Methods for Simulating Survival Data for Expected Value of Sample Information Calculations

    Dec 1, 2022, 00:00

  • EE136 Cost of Illness in Patient With Synovial Sarcoma in México (2010-2021)

    Dec 1, 2022, 00:00

  • HPR165 Defining a Global Disease Budget for HIV in Greece

    Dec 1, 2022, 00:00

  • EE194 Modelling Long-Term Clinical Outcomes of Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in the United States

    Dec 1, 2022, 00:00

  • HTA10 Carer Health-Related Quality of Life in National Institute for Health and Care Excellence (NICE) Appraisals: An Update of the Pennington Review

    Dec 1, 2022, 00:00

  • HTA130 Value Contribution of Olipudase Alfa Therapy for the Treatment of Non-Central Nervous System Manifestations of Acid Sphingomyelinase Deficiency (ASMD) by Multi-Criteria Decision Analysis (MCDA)

    Dec 1, 2022, 00:00

  • RWD118 Characterisation of Surgical Aortic Valve Replacements for Aortic Regurgitation in Spain During 2016-2019

    Dec 1, 2022, 00:00

  • HPR88 Burden and Cost of Rotator Cuff Repair Surgery and Reimbursement of Its Treatment in a Developing Country: An Observational Study in Indonesia

    Dec 1, 2022, 00:00

  • RWD150 Characteristics of Plaque Psoriasis Patients Initiating Guselkumab by Country: A Multi-National, Real-World Survey of Dermatology Practices

    Dec 1, 2022, 00:00

  • PCR214 The Value of Technology to Reduce Barriers to Clinical Trial Diversity and Facilitate the Development of Patient-Centric Medicine

    Dec 1, 2022, 00:00

  • EPH202 Use of National Healthcare Information Databases to Assess Sex Differences in Patient Care in Spain: The Case of Asthma (2017-2020)

    Dec 1, 2022, 00:00

  • MT34 The Dynamic and Context-Specific Value of a Medical Test - A Health Economic Perspective

    Dec 1, 2022, 00:00

  • EPH123 Estimating ADHD Prevalence and ADHD-Associated Health Care Costs Based on Claims Data

    Dec 1, 2022, 00:00

  • EE519 Cost Effectiveness Analysis of Avacopan in Antineutrophil Cytoplasm Antibody-Associated Vasculitis - A Canadian Perspective

    Dec 1, 2022, 00:00

  • HPR181 Towards Understanding the Value of Consequences in the Context of Watch-and-Wait Versus Surgery for People With Rectal Cancer Achieving Clinical Complete Response

    Dec 1, 2022, 00:00

  • HTA200 Do Pharmacoeconomic Analyses Impact Price Negotiation Outcomes in Canada? Comparison of Rare Disease and Oncology Drugs

    Dec 1, 2022, 00:00

  • PCR263 What Does the EQ-5D-Y-5L Measure in Comparison to Other Generic Paediatric Health Related Quality of Life Instruments?

    Dec 1, 2022, 00:00

  • EE46 High Doses of Treprostinil Could Entail Lower Hospitalization Costs in Patients With Pulmonary Arterial Hypertension in Nine European Countries

    Dec 1, 2022, 00:00

  • HPR29 Assessing the Feasibility of Implementing Indication-Based Pricing in Sweden: A Qualitative Analysis

    Dec 1, 2022, 00:00

  • EE177 A Budget Impact Analysis of a Novel Diagnostic Test to Differentiate Viral/Bacterial Etiology for Community-Acquired Pneumonia Patients Presenting to the Emergency Departments in Italy

    Dec 1, 2022, 00:00

  • HTA266 Hierarchical Network Meta-Analysis Models for the Inclusion of Randomised and Observational Comparative Studies in Evidence Synthesis

    Dec 1, 2022, 00:00

  • EE245 Impact of Modelling the Inclusion of Productivity Losses in Economic Analyses of Vaccines for Clostridioides Difficile Infections and Respiratory Syncytial Virus

    Dec 1, 2022, 00:00

  • PCR213 Rehabilitation After Hip Replacement Surgery in the State and Private Health Care in Hungary

    Dec 1, 2022, 00:00

  • HTA23 Restrictions and Real-World Evidence Requirements in the Health Technology Assessment of Gene Therapy Medicinal Products in Europe, Canada, Australia, and the United States

    Dec 1, 2022, 00:00

  • EPH148 Knowledge of Abortion and Perception Towards Legalization of Abortion Among Students in a Nigerian University

    Dec 1, 2022, 00:00

  • HPR155 The Use of Patient-Reported Outcomes for New Drugs Approval in Europe: A Review of European Public Assessment Reports From 2017 to 2021

    Dec 1, 2022, 00:00

  • RWD88 Examining the Fitness-for-Purpose of European Real-World Data Sources for External Comparators in Haematological Malignancies

    Dec 1, 2022, 00:00

  • EPH72 Relationship Between the Number of Approved Cancer Treatments and Unmet Need in Europe

    Dec 1, 2022, 00:00

  • PCR37 Understanding Symptoms and Meaningful Change in Patient Global Impression Scales for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (adv/met NSCLC): A Qualitative Research Study

    Dec 1, 2022, 00:00

  • EE171 Hospital Costs of Muscle-Invasive Urothelial Carcinoma (MIUC) Patients Undergoing Radical Surgery: A French Real-World Retrospective Study Based on the National Hospitalization Database (PMSI)

    Dec 1, 2022, 00:00

  • EPH155 A Systematic Review of the Impact of Vaccination on Long COVID

    Dec 1, 2022, 00:00

  • EE65 Budget Impact of Zanubrutinib for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia in the United States

    Dec 1, 2022, 00:00

  • EE373 Assessment of Extent and Quality of Pharmacoeconomic Studies in India Using Quality of Health Economic Studies (QHES) Score: A Targeted Literature Review

    Dec 1, 2022, 00:00

  • EPH109 Impact of COVID-19 Pandemic on HPV Vaccine Initiation Rates in Adolescent Girls: Projected Time to Reverse Dose Deficits in France

    Dec 1, 2022, 00:00

  • HPR175 Is International Reference Pricing Applied Consistently at Pharmaceutical Price Re-Evaluation for Retail and Specialty Products?

    Dec 1, 2022, 00:00

  • EE231 Use of Biomarkers in Health Care: What Health Economic Methods Are Used to Evaluate Them?

    Dec 1, 2022, 00:00

  • SA20 Clinical, Humanistic, and Economic Burden in Fibrodysplasia Ossificans Progressiva (FOP): A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE379 Potential Healthcare Resource Use and Associated Costs of Every 2-Months Injectable Cabotegravir+Rilpivirine Long-Acting Implementation in the Spanish NHS vs Daily Oral HIV Treatments

    Dec 1, 2022, 00:00

  • P50 Methods to Acknowledge Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature

    Dec 1, 2022, 00:00

  • PCR174 Valuation of the EQ-5D-3L in Jordan

    Dec 1, 2022, 00:00

  • EE378 Cost-Effectiveness Analysis of a Digital Health Application (DIGA) Plus Best Supportive Care (BSC) Compared to BSC in German Episodic Migraine Patients

    Dec 1, 2022, 00:00

  • EE264 Predictions on the Health and Economic Effects for the Chilean Population With Type 2 Diabetes Mellitus Recently Diagnosed

    Dec 1, 2022, 00:00

  • HSD44 The Concentration of Missed Appointments Within a Medicaid Accountable Care Organization

    Dec 1, 2022, 00:00

  • PCR142 Adaptation of the Urticaria Patient Daily Diary for Caregiver Completion in Pediatric Chronic Spontaneous Urticaria

    Dec 1, 2022, 00:00

  • HTA67 Do Manufacturers Still See Value in Submitting Evidence for a NICE Appraisal in England? Comparing and Contrasting Terminated Appraisals Between Oncology and Non-Oncology and Monotherapies and Combination Products

    Dec 1, 2022, 00:00

  • EE382 Cost-Utility Analysis of Avacopan for the Treatment of Anca-Associated Vasculitis (AAV) Patients in the UK

    Dec 1, 2022, 00:00

  • PCR81 Patient-Centered Benefit-Risk Assessment of a Novel Therapy for Alopecia Areata

    Dec 1, 2022, 00:00

  • PCR249 Responder Analysis of the Patient Life Interference Questionnaire in Children With Growth Hormone (GH) Deficiency Treated With Either Injections of Once Weekly GH (Somatrogon) or Once Daily GH (Genotropin) in a Phase 3 Trial

    Dec 1, 2022, 00:00

  • EE13 Cost-Utility Analysis of Dupilumab for the Treatment of Severe Atopic Dermatitis in Children and Adolescents in Portugal

    Dec 1, 2022, 00:00

  • CO156 The Comparative Postoperative Outcomes between Robotic-Assisted Lobectomy and Video-Assisted Thoracoscopic Surgery for Treating Lung Cancer in Japan

    Dec 1, 2022, 00:00

  • EPH62 Estimation of Patients With Psoriasis Potentially Eligible to Biologic Agents and Not Currently Treated With These Therapies: Analysis of Real-World Data in Italy

    Dec 1, 2022, 00:00

  • HPR137 Resource Utilization Trends Related With Precision Oncology in Chile

    Dec 1, 2022, 00:00

  • HTA82 Health Technology Assessment of Hospital Medicines in Denmark: A Review of DMC Decisions (2017-2022)

    Dec 1, 2022, 00:00

  • EE159 Economic Burden of Malignant Pleural Mesothelioma in Europe: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • RWD113 Differences in Adverse Events Reporting Between Natural Products Versus Prescription Products in the United States and Canada

    Dec 1, 2022, 00:00

  • EE479 Economic and Humanistic Burden of Visual Impairment and Blindness in Brazil: A Grey Literature Review

    Dec 1, 2022, 00:00

  • HPR135 Are Managed Entry Agreements a Feasible Approach to Improve Patient Access to Innovative Therapies in Latin America?

    Dec 1, 2022, 00:00

  • HPR199 Public Procurement of Medicines: A Taxonomy of Procurement Systems in Europe

    Dec 1, 2022, 00:00

  • EE555 Direct Cost of Percutaneous Deep Vein Arterialization (PDVA) in an Italian Center

    Dec 1, 2022, 00:00

  • RWD122 Strengthening the Patient Voice in Health Outcome Measurement in Real-World Data in Europe – The Health Outcomes Observatory

    Dec 1, 2022, 00:00

  • HSD64 Drug Discontinuation and Healthcare Cost Evaluation in Crohn's Disease Patients Under Biologic Therapy: An Italian Retrospective Analysis

    Dec 1, 2022, 00:00

  • EE647 Real-Word Effectiveness and Cost Consequence of Antipsychotic Treatment Choices in the Treatment of Schizophrenia in Italy: A Bayesian Hierarchical Inference Model

    Dec 1, 2022, 00:00

  • PCR86 Humanistic Burden of Informal Caregivers of Children and Young Adults With Newly Diagnosed Type 1 Diabetes (T1D): A Systematic Literature Review (SLR)

    Dec 1, 2022, 00:00

  • PCR102 Development of Conceptual Frameworks and PRO Measures in Ornithine Transcarbamylase Deficiency

    Dec 1, 2022, 00:00

  • HTA138 Association of NCPE Submission Outcomes in Ireland With Additional Benefit Ratings in Germany

    Dec 1, 2022, 00:00

  • MSR110 A Comparison of Stan Versus WinBUGS Software for Conducting Bayesian Hazard Ratio-Based Network Meta-Analysis

    Dec 1, 2022, 00:00

  • EPH129 Hospitalizations for Chemotherapy-Induced Febrile Neutropenia in Patients With Lung Cancer in France From 2017 to 2020

    Dec 1, 2022, 00:00

  • EE128 Facing the Challenge of Ageing: Cost-Effectiveness of the SPRINT-T Protocol

    Dec 1, 2022, 00:00

  • EE395 A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients With Inflammatory Bowel Disease in the United Kingdom

    Dec 1, 2022, 00:00

  • RWD65 Burden of Developmental Disabilities and Ethnic Differences in Utilization of Non-Pharmacotherapies Among Children in the US

    Dec 1, 2022, 00:00

  • EE296 Cost-Effectiveness of Faricimab in Patients With Neovascular Age-Related Macular Degeneration in Canada

    Dec 1, 2022, 00:00

  • EPH7 A Survey of the Occurrence and Transmission of COVID-19 in Outdoor Education Settings in Canada

    Dec 1, 2022, 00:00

  • RWD20 Changes in Clinical and Pathological Characteristics of Newly Diagnosed Breast Cancer Patients in Hungary: A 10-Year Retrospective Analysis

    Dec 1, 2022, 00:00

  • HSD106 Analysis of Diagnostic and Medical Delay Data Among Lung Cancer Patients in 2019 and 2020

    Dec 1, 2022, 00:00

  • PCR82 Association between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and Eq-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities

    Dec 1, 2022, 00:00

  • HSD16 PCSK-9 Inhibitors for the Control of Hypercholesterolemia: Eligibility for Treatment, Prescription Appropriateness and Outcomes, in a Real-World Clinical Setting

    Dec 1, 2022, 00:00

  • EE318 Evaluating the Cost Effectiveness of the Towards Home-Based Albuminuria Screening (THOMAS) Study for Early Detection and Treatment of Chronic Kidney Disease

    Dec 1, 2022, 00:00

  • EE179 Cost-Effectiveness of Robot-Assisted Total Hysterectomy for Benign Pathologies Compared to Laparoscopic and Open Surgery: A Retrospective Study

    Dec 1, 2022, 00:00

  • HSD77 Evaluation of a Transitional Care Strategy Implemented in Hospitalized Adults With High-Risk and Multimorbidity in Chile

    Dec 1, 2022, 00:00

  • EPH32 Investigation of the Correlations Between Premenstrual Syndrome, Physical Activity, Perceived Stress and Mental State Based on Cross-Sectional Research

    Dec 1, 2022, 00:00

  • HSD27 Constrained Optimization Model to Estimate Best Booster Allocation Strategy to Minimize Hospital Bed-Days Under a Fixed Healthcare Budget

    Dec 1, 2022, 00:00

  • EPH101 Application Processes for International Classification of Disease (ICD)-11 Update and Revision Proposals

    Dec 1, 2022, 00:00

  • EE365 Cost-Minimization and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Compared With Acalabrutinib in the First Line and R/R Chronic Lymphocytic Leukemia From the Brazilian Private Healthcare Perspective

    Dec 1, 2022, 00:00

  • RWD149 Reduction in Ischemic Stroke Rates in Patients With Non-Valvular Atrial Fibrillation During the Period 2013-2020: A Real-Life Study in Spain

    Dec 1, 2022, 00:00

  • EE38 Cost-Minimization Analysis of Damoctocog Alfa Pegol With the Treatment of Hemophilia A in Turkey

    Dec 1, 2022, 00:00

  • EPH27 Examining the Risk Behaviour of Young People

    Dec 1, 2022, 00:00

  • EE482 Costs of Proton Therapy During the Start-up Phase Using Time-Driven Activity-Based Costing in the Netherlands

    Dec 1, 2022, 00:00

  • EE228 A Review of Treatment Effect Waning Methods for Immuno-Oncology Therapies in National Institute for Health and Care Excellence Technology Appraisals

    Dec 1, 2022, 00:00

  • SA52 Indirect Comparison of Short-, Mid-, and Long-Term Efficacy of Treatments for Moderate to Severe Plaque Psoriasis: A Systemic Review and Network Meta-Analysis

    Dec 1, 2022, 00:00

  • MSR132 Integrating Relative Survival Framework for Survival Extrapolation in Multi-State Models—An Application to Predicting Quality-Adjusted Life Years for Chronic Myeloid Leukemia Patients

    Dec 1, 2022, 00:00

  • HPR3 Country Score Tool for Readiness Assessment and Evidence Generation of Immunization Programs in Ageing Adults in Europe

    Dec 1, 2022, 00:00

  • HPR74 International Reference Pricing Analysis of Medicines in Turkiye By 2021

    Dec 1, 2022, 00:00

  • A Qualitative Investigation of Older Adults’ Conceptualization of Quality of Life and a Think-Aloud Content Validation of the EQ-5D-5L, SF-12v2, Warwick Edinburgh Mental Wellbeing Scale, and Office of National Statistics-4.

    Dec 1, 2022, 00:00

  • RWD45 Real-World Data to Support Surrogate Endpoint Evaluation for Health Technology Assessment

    Dec 1, 2022, 00:00

  • EE573 Evaluating the Economic Burden of Metastatic Urothelial Carcinoma (mUC): A Real-World Analysis Using Hungarian Claims Data

    Dec 1, 2022, 00:00

  • EE80 The Potential Clinical and Economic Benefits of a Next Generation Omicron-Containing (BA.1) Bivalent Sars-Cov-2 Booster Compared to First Generation Prototype Boosters in Germany Assuming BA.4/BA.5 Dominance

    Dec 1, 2022, 00:00

  • RWD10 Measuring Patient Satisfaction From Patient Reported Outcomes (PRO) Application Embedded in the Hospital's Treatment Pathway in Finland

    Dec 1, 2022, 00:00

  • EE405 A UK Cost-Minimisation Analysis of Brolucizumab Versus Aflibercept in Diabetic Macular Oedema (DMO)

    Dec 1, 2022, 00:00

  • RWD13 Real World Criteria Used to Diagnose Relapsed/Refractory Status of Patients With Multiple Myeloma in Germany

    Dec 1, 2022, 00:00

  • HPR22 Eight Years on, to What Extent Have Patients Benefitted from the UK's Early Access to Medicines Scheme (EAMS)?

    Dec 1, 2022, 00:00

  • EE30 An Economic Evaluation of Direct Oral Anticoagulants for Venous Thromboembolism in Thailand

    Dec 1, 2022, 00:00

  • MSR19 An Update on Real-Time Application of Machine Learning Programs to Improve Cardiovascular Risk Prediction in European Population

    Dec 1, 2022, 00:00

  • HSD110 Risk Estimation and Risk Prediction of Unmet Healthcare Needs of Disaster Victims Using Machine Learning

    Dec 1, 2022, 00:00

  • EE587 Cost-Effectiveness of Device-Based Long-Term Cardiac Monitoring in High-Risk Post-Myocardial Infarction Patients

    Dec 1, 2022, 00:00

  • EE447 Budget Impact Analysis of Tepotinib in England for Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) Harboring MET Exon 14 (METex14) Skipping

    Dec 1, 2022, 00:00

  • RWD51 Demonstrating Internal and External Validity in Real-World Datasets: A Case Study in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2022, 00:00

  • MT2 Rate of Complete Spectacle Independence With a Trifocal IOL: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • EPH67 Sleep Disorders, Depression, Anxiety, and Stress During the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • HPR132 Budget Cap With Pay Back As Managed Entry Agreement Policy: Bulgarian Example for Rheumatology Medicines

    Dec 1, 2022, 00:00

  • EE507 Insulin Degludec/Insulin Aspart Versus Basal+Bolus Insulin Treatment (Insulin Glargine U100 Insulin Aspart) in T2D in India: A Short-Term Cost-Effectiveness Analysis Based on the Step-By-Step Clinical Trial

    Dec 1, 2022, 00:00

  • PCR275 Patient Experience With Anti–Vascular Endothelial Growth Factor (VEGF) Therapy in Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME): A Multinational Survey

    Dec 1, 2022, 00:00

  • HTA128 Reassessment of Orphan Drugs After Exceeding the 50 Mio. Euro Revenue Threshold: Effects on Added Benefit and Price Discount

    Dec 1, 2022, 00:00

  • EPH1 Impact of YAG Laser Capsulotomy Procedures on Cataract Center Chair Time and Revenue Opportunity- A Cost Consequence Analysis at a Private Facility in India

    Dec 1, 2022, 00:00

  • EPH104 Valuing the Impact of Incorporating an Acellular Hexavalent Vaccine in the National Vaccination Scheme of Peru in the Context of COVID-19

    Dec 1, 2022, 00:00

  • EE468 Healthcare Resource Utilisation and Costs Associated With the Management of Hospitalised COVID-19 Patients in England

    Dec 1, 2022, 00:00

  • EE602 Budget Impact Analysis of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate for COPD in the Italian Healthcare System

    Dec 1, 2022, 00:00

  • HSD15 Biosimilars and Originators: Utilization and Costs in Lombardy Region

    Dec 1, 2022, 00:00

  • EE346 Comparison of Diagnosis, Administration, and Treatment-Related Cost of Targeted Radiopharmaceutical Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC) From a Third-Party Payer Perspective

    Dec 1, 2022, 00:00

  • HSD22 Wet Age-Related Macular Degeneration: Trends in Real-World Treatment Patterns in the United States

    Dec 1, 2022, 00:00

  • EE535 The Evolution of Peer Reviewed Publications on the Subject of Economic Evaluation

    Dec 1, 2022, 00:00

  • EE523 Assessing the Economic and Quality of Life Impact of Treatment in Duchenne Muscular Dystrophy

    Dec 1, 2022, 00:00

  • EE589 Cost-Effectiveness of Once-Daily Somatropin From Sandoz Versus Once-Weekly Somatrogon for the Treatment of Growth Hormone Deficiency in Children and Adolescents

    Dec 1, 2022, 00:00

  • PCR245 'Please Complete Your Surveys:' A Targeted Review of Adherence Rates in Real-World Studies Using Digital Technologies

    Dec 1, 2022, 00:00

  • Disparities in Access to Radiation Therapy by Race and Ethnicity in the United States With Focus on American Indian/Alaska Native People

    Dec 1, 2022, 00:00

  • EPH174 Utilization of Intravenous Iron Preparations for Iron Deficiency Anemia: A Longitudinal Study Using a Japanese Health Insurance Claims Database With Annual Health Check-Ups in 2018-2021

    Dec 1, 2022, 00:00

  • HSD31 Analysis of the Balanced Scorecard's Managerial Subdimensions in Health Care Organizations During the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • EE368 A Three Years Budget Impact Analysis of Hemanext in Italy

    Dec 1, 2022, 00:00

  • HSD24 Evaluation of the Effectiveness of the Chest Pain Unit Department in Outcomes of Patients With Acute Coronary Syndrome

    Dec 1, 2022, 00:00

  • RWD46 Validation of Race in Cerner Real-World Data: Understanding Missing and Uninterpretable Data

    Dec 1, 2022, 00:00

  • HPR5 Reimbursement of Pharmaceuticals in Turkey: Comparison With Approvals of the FDA Between 2010-2021

    Dec 1, 2022, 00:00

  • EE208 Direct Cost and Indirect Cost of Ischemic Stroke in China

    Dec 1, 2022, 00:00

  • PCR256 Humanistic Burden and Prevalence of Mental Conditions Among COVID-19 Patients in Japan and China

    Dec 1, 2022, 00:00

  • HPR211 China Drug Market Changes: How to Navigate the Future of Reimbursement in China?

    Dec 1, 2022, 00:00

  • CO14 Patient-Reported Outcomes (PROS) With Ramucirumab Versus Placebo in Chinese Patients With Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein From the Randomized Phase 3 Reach-2 Study

    Dec 1, 2022, 00:00

  • HPR77 Variables Impacting Drugs Average Prices in Italy in 2016 - 2021 Period

    Dec 1, 2022, 00:00

  • CO164 Real-World Outcomes and Treatments Patterns of Metastatic Castration-Resistant Prostate Cancer Patients: An Italian Retrospective Study

    Dec 1, 2022, 00:00

  • RWD135 Cost of Care of Elderly (65 Years and Above)

    Dec 1, 2022, 00:00

  • MT20 Improving Perioperative Efficiency in the Management of Surgical Sets for Trauma Surgeries: The 4S Approach

    Dec 1, 2022, 00:00

  • CO154 Differences in Clinical Utility Between Thermocool SmartTouch® Surround Flow Catheter and Smarttouch or Surround Flow Catheter for Arial Fibrillation Ablation: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • EE229 Cost-Effectiveness Analysis of Eremumab (Aimovig®) for the Preventive Treatment of Migraine in Spain

    Dec 1, 2022, 00:00

  • EE484 Cost-Effectiveness Analysis of Sodium Zirconium Cyclosilicate for Treating Hyperkalemia Among Chinese Patients

    Dec 1, 2022, 00:00

  • EE461 Cost-Effectiveness of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence With Tumor Cell Pd-L1 Expression ≥ 1% in Denmark

    Dec 1, 2022, 00:00

  • PCR209 Burden of Chronic Inducible Urticaria Relative to Psoriasis and Atopic Dermatitis in Five European Countries (France, Germany, Italy, Spain, and United Kingdom)

    Dec 1, 2022, 00:00

  • HTA237 Cost-Effectiveness Analysis of Ofatumumab for Relapsing Remitting Multiple Sclerosis Treatment in Italy

    Dec 1, 2022, 00:00

  • SA27 Comparison of Comorbidity Indices Between Electronic Health Records (EHR) Derived Database and Claims Data Among Patients With Metastatic Breast Cancer

    Dec 1, 2022, 00:00

  • CO90 A Systematic Literature Review of Prognostic Factors and Surrogate Endpoint Analyses in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

    Dec 1, 2022, 00:00

  • SA56 A Targeted Literature Review Exploring Surrogacy Relationships Between Estimated Glomerular Filtration Rate (EGFR) and Left Ventricular Mass Index (LVMI) in Clinical Events in Fabry Disease

    Dec 1, 2022, 00:00

  • EE389 Medical Cost Reduction in Rural Residents Through a Health Promotion Program in Japan

    Dec 1, 2022, 00:00

  • PCR207 Exploring and Addressing the Educational Needs of COPD Patients Through a Multinational Qualitative Survey Focused on Exacerbations: Results of the Romanian Cohort (Exacerbation Free)

    Dec 1, 2022, 00:00

  • MT5 Adjusted Polygenic Risk Score Enables Personalized Cardiovascular Disease Prevention and Clinical Management

    Dec 1, 2022, 00:00

  • HPR61 Cannabis Edibles: Using a Discrete Choice Experiment to Explore Patterns of Purchase Preferences Among Canadians

    Dec 1, 2022, 00:00

  • HTA235 Time to Health Technology Assessment of New Medicinal Products in Greece

    Dec 1, 2022, 00:00

  • HPR122 Cost-Based vs Value-Based - How Do Japan's and Germany's Pricing Frameworks Compare?

    Dec 1, 2022, 00:00

  • MSR73 Development and Preliminary Validation of Brief Participant-Reported Questionnaire Modules to Measure the Use of Informal Care, Social Care and Personal Expenses

    Dec 1, 2022, 00:00

  • EE645 The Effect of Opioid Use on Sick Leave Among Patients With Osteoarthritis Undergoing Joint Replacement: A Propensity Score Adjustment Approach

    Dec 1, 2022, 00:00

  • OP2 Organizational Impact Model Associated With Switching From Intravenous (IV) to Subcutaneous (SC)

    Dec 1, 2022, 00:00

  • HTA139 Swedish Health Technology Assessment Outcomes and Considerations for Advanced Therapy Medicinal Products

    Dec 1, 2022, 00:00

  • PCR283 Health-Related Quality of Life in Patients With Advanced or Recurrent Endometrial Cancer Who Have Disease Progression on or Following Prior Treatment With a Platinum-Containing Therapy: Analysis of EQ-5D Utility Scores

    Dec 1, 2022, 00:00

  • HPR112 The Average Monthly Income of Full-Time Doctors Working in Hospitals by Type of Healthcare Institution in Hungary

    Dec 1, 2022, 00:00

  • EE653 Efficacy of Targeted Drugs for the Treatment of Adults With Moderate-to-Severe Plaque Psoriasis in the Russian Federation: Number Needed to Treat and Costs Per Responder

    Dec 1, 2022, 00:00

  • EPH185 Increased Influenza Vaccine Coverage Rate Following COVID-19: Durable Trend or Epiphenomenon?

    Dec 1, 2022, 00:00

  • EE423 Cost-Effectiveness of Vaccinating Adults ≥65 Years and at-Risk Individuals 18-64 Years With the 20-Valent Pneumococcal Conjugate Vaccine Versus Currently Recommended Vaccine Regimens in Sweden

    Dec 1, 2022, 00:00

  • EE241 Health Economic Model for Estimating the Cost Impact of Optimized Peripheral Intravascular Catheter Insertion and Post-Insertion Catheter Care

    Dec 1, 2022, 00:00

  • HPR108 Impact of COVID-19 Pandemic on the Decision Process of the Italian Medicine Agency: A Quantitative Assessment

    Dec 1, 2022, 00:00

  • HTA40 Did You Just Get a NICE Increase in Price Potential? Severity Multipliers and Price Potential in England

    Dec 1, 2022, 00:00

  • EE95 Economic Burden of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Colombia

    Dec 1, 2022, 00:00

  • HPR143 Why It Is So Difficult to Calculate Bundled Payments? Learnings From a Practical Case in Germany

    Dec 1, 2022, 00:00

  • CO105 Long-Term Benefit of Ataluren Treatment in Non-Sense Duchenne Muscular Dystrophy Versus Standard of Care

    Dec 1, 2022, 00:00

  • HPR130 Comparison of Diagnosis-Based Risk Adjustment Models for Episode-Based Cost

    Dec 1, 2022, 00:00

  • EE597 Conducting Budget Impact Analysis (BIA) for Multiple HTA of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—There Is More Than Meets the Eye

    Dec 1, 2022, 00:00

  • HTA155 The Use of Patient Reported Outcomes in Aiding the Reimbursement Decisions of Advanced Medicinal Therapy Products

    Dec 1, 2022, 00:00

  • HSD47 Evidence Synthesis on Inappropriate Use of Clinical Practices in Spain: A Scoping Review

    Dec 1, 2022, 00:00

  • RWD101 Impact of COVID-19 Vaccination in Reducing Standard Hospitalization Cost Among COVID-19 Patients in the US – A Retrospective Study

    Dec 1, 2022, 00:00

  • CO123 An Indirect Comparison of Efgartigimod Versus Rituximab for Generalized Myasthenia Gravis

    Dec 1, 2022, 00:00

  • PCR251 Retrospective Social Listening Study of Patients Living with Systemic Lupus Erythematosus (SLE): Understanding the Patient Experience

    Dec 1, 2022, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2022, 00:00

  • Preference Variation: Where Does Health Risk Attitude Come Into the Equation? [Editor's Choice]

    Dec 1, 2022, 00:00

  • Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs—Can Alignment Be Enhanced? [Editor's Choice]

    Dec 1, 2022, 00:00

  • EE384 A Targeted Literature Review of Health State Utility Values in Neuromyelitis Optica Spectrum Disorder

    Dec 1, 2022, 00:00

  • EE129 Cost-Effectiveness of Ofatumumab Versus Ocrelizumab in Patients With Active Relapsing Multiple Sclerosis in Portugal

    Dec 1, 2022, 00:00

  • EE512 Comparing Costs of Immune Checkpoint Inhibitors for Treatment of 1L NSCLC in Colombia – A Cost Minimisation Analysis

    Dec 1, 2022, 00:00

  • MSR10 Applying Sequence Clustering Methods to Characterize Healthcare Pathways of Patients at Different Prostate Cancer Stages in the French Nationwide Healthcare Database (SNDS)

    Dec 1, 2022, 00:00

  • HTA163 Development of SF-6Dv2 Health Utility Weights in the United States

    Dec 1, 2022, 00:00

  • EE57 Recombinant Zoster Vaccine for High-Risk Ageing Adults in the Netherlands: Cost-Effectiveness and Value of Information Analyses

    Dec 1, 2022, 00:00

  • EPH19 Long Term Epidemiological Impact of Adjuvant Atezolizumab in Preventing the Recurrence of Early PDL1 High Non-Small Cell Lung Cancer in Europe

    Dec 1, 2022, 00:00

  • PCR50 Measuring Health From a Broad Perspective: Preferences Assessed Among Various Professional Stakeholder Groups

    Dec 1, 2022, 00:00

  • HTA84 Real-World Assessment of Orphan Drugs via the New Joint Clinical Assessment Route in Europe

    Dec 1, 2022, 00:00

  • PCR260 Cross-Sectional Quantitative Evaluation of a Novel Patient-Reported Outcome Measure in Familial Chylomicronemia Syndrome

    Dec 1, 2022, 00:00

  • EPH6 Non-Muscle-Invasive Bladder Cancer: A Review of Burden and Unmet Need

    Dec 1, 2022, 00:00

  • EE257 Cost-Effectiveness Analysis of AI-Assisted Radiological Assessment in Patients With Relapsing Remitting Multiple Sclerosis in the UK

    Dec 1, 2022, 00:00

  • MSR101 Predicting Overall Survival of Immune-Checkpoint Inhibitors (ICIS): Which Distributions Are the Most Accurate? A Systematic Literature Review and Extrapolations of French Cost-Effectiveness Report Assessments

    Dec 1, 2022, 00:00

  • EE227 Healthcare Resource Utilization and Costs Among Patients with Moderately-to-Severely Active Crohn’s Disease Treated with Ustekinumab: Real-World Evidence

    Dec 1, 2022, 00:00

  • P3 How Much Did the COVID-19 Shielding Policy Cost in Wales? Results of a Cost Analysis Within the EVITE Immunity Evaluation

    Dec 1, 2022, 00:00

  • HSD65 Portuguese Clinical Practice in the Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

    Dec 1, 2022, 00:00

  • EE244 Cost of nAMD Management in 3R Level Hospitals in Spain. Comparison of Unitary Cost System vs National Cost Database

    Dec 1, 2022, 00:00

  • RWD73 Epidemiology and Burden of Sickle Cell Disease in Fran Real-Life Analysis Using Data From the Echantillon Generaliste Des Bénéficiaires (EGB)

    Dec 1, 2022, 00:00

  • EPH98 An Approach to Gender Disparities Through the Evaluation of Sex Differences in Hospital Diagnoses in Spain 2016-2020

    Dec 1, 2022, 00:00

  • HPR16 Comparison of Outcomes-Based Reimbursement (OBR) Schemes in Europe and the US for CAR-T Cell Therapy: Tisagenlecleucel

    Dec 1, 2022, 00:00

  • PCR104 The Risk of Developing Diabetes and Impaired Health-Related Quality of Life in Indonesia

    Dec 1, 2022, 00:00

  • RWD80 The Disease Burden of Invasive Candidiasis in Germany: A Non-Interventional, Retrospective Cohort Analysis of Real-World Data

    Dec 1, 2022, 00:00

  • RWD7 Need for Real-World Evidence in Consumer Health Setting and Its Potential Benefits

    Dec 1, 2022, 00:00

  • PCR64 Patient Satisfaction With 6-Monthly Versus 3-Monthly Paliperidone Palmitate Long-Acting Injectable for Schizophrenia Treatment: Results From a Phase-3, Randomised, Noninferiority Study

    Dec 1, 2022, 00:00

  • EE74 Costing for Socioeconomic Impact Analysis: Implications of Adopting a Patient's Perspective

    Dec 1, 2022, 00:00

  • EE190 Association of Total Annual Costs of Duchenne Muscular Dystrophy With Disease Severity

    Dec 1, 2022, 00:00

  • EE96 Budget-Impact Analysis of Adopting Expanded Hemodialysis (HDX) Via Theranova® in Korea

    Dec 1, 2022, 00:00

  • CO34 Phase Angle, Quality of Life and Survival in Women With Head and Neck Cancer: An Uncommon Condition

    Dec 1, 2022, 00:00

  • HSD88 Female Pharmacy Student's Intention to Work in Community Pharmacy in Saudi Arabia: Using the Theory of Planned Behavior

    Dec 1, 2022, 00:00

  • CO148 Time in Remission as an Alternative Outcome Measure for Ankylosing Spondylitis: A 4-Year Prospective Study of 1900 Users of Anti-TNF

    Dec 1, 2022, 00:00

  • RWD12 Medication Adherence and Quality of Life of Patients With Multiple Sclerosis in Bulgaria - A Pilot Study

    Dec 1, 2022, 00:00

  • P51 A Discrete Choice Experiment to Understand the Value of Equity

    Dec 1, 2022, 00:00

  • MT25 Mobile Health Interventions in Mental Health Conditions: A Review on Development So Far and Gaps to Be Bridged

    Dec 1, 2022, 00:00

  • EE513 Health Economic Evaluation Incorporating Mixture Cure Survival Analysis of Nivolumab Plus Ipilimumab for Previously Untreated Metastatic NSCLC

    Dec 1, 2022, 00:00

  • EE649 Contrasting 4 Different Mortality Predictions in Patients With Type 1 Diabetes Using the IQVIA Core Diabetes Model

    Dec 1, 2022, 00:00

  • EPH161 Public Health Impact and Cost-Effectiveness Analysis of Universal Varicella Vaccination in the United Kingdom

    Dec 1, 2022, 00:00

  • PCR133 Subjective Financial Toxicity and Health-Related Quality of Life in Cancer Patients and Survivors: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • SA6 Challenges in Economic Modelling of Adjuvant Cancer Therapy for Health Technology Assessments

    Dec 1, 2022, 00:00

  • MSR89 Evaluating Prediction Model Calibration at the Moderate-Strong Level Using Patient Subgroups Identified With Clustering Analysis

    Dec 1, 2022, 00:00

  • EE34 Determining Cost Data for Fertility Treatment in Different European Settings

    Dec 1, 2022, 00:00

  • PCR183 Does the Format of Educational Materials Impact Diabetes Patient Preferences for Glucose Monitoring Technology: A Randomized Study in Two Countries

    Dec 1, 2022, 00:00

  • RWD153 Attributable Costs of Breast Cancer in Colombia: A Cost-of-Illness Study Based on Administrative Claims Databases

    Dec 1, 2022, 00:00

  • CO149 Epidemiology and Burden of Oral Complications Following Breast Cancer Treatment - A Systematic Literature Review (PROSPERO CRD42021272130) - Mucositis and Stomatitis Incidence From Randomized Trials

    Dec 1, 2022, 00:00

  • Advances in Cost-Effectiveness Analysis Methods

    Dec 1, 2022, 00:00

  • CO166 Clinical Outcomes of Patients With Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion Cancer Treated With Non-Tropomyosin Recepter Kinase Inhibitors: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • P38 One Size Does Not Fit All: Calculating the Cost-Effectiveness of Multiple Indications of Pembrolizumab in the Netherlands

    Dec 1, 2022, 00:00

  • PCR126 Patient-Reported Experience With Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea – Results From a Pilot Study in Germany

    Dec 1, 2022, 00:00

  • EPH36 Taking a Bite Out of Claims Data to Provide Insights into Rare Events: A Descriptive Analysis of Shark, Pig, and Raccoon Bite Patients in the U.S.

    Dec 1, 2022, 00:00

  • MT36 Use of Mobile Health (MHEALTH) Applications in Cancer: A Trend Analysis

    Dec 1, 2022, 00:00

  • CO20 Predicted Time to Wheelchair and Ventilation Events Comparing Avalglucosidase Alfa (AVA) Versus (vs) Alglucosidase Alfa (ALG) Using a Model of Late-Onset Pompe Disease (LOPD)

    Dec 1, 2022, 00:00

  • EE238 Protocol for an EQ-5D-5L Elicitation Study Regarding Health State Valuations for Surviving Patients at Intensive Care Units

    Dec 1, 2022, 00:00

  • PCR277 Nutritional Status Assessment in Patients With Lung Cancer

    Dec 1, 2022, 00:00

  • HPR41 Project Orbis to Accelerate Patient Access to Innovative Cancer Therapies: A Narrative Review

    Dec 1, 2022, 00:00

  • EE64 Healthcare Resource Utilisation and Medical Costs Among Patients With High-Grade Serous Ovarian Cancer in a Real-Life Setting in Finland: The OCRWE-Finland Study

    Dec 1, 2022, 00:00

  • HTA11 U.S. Commercial Payer and Rare Disease Patient Stakeholder Perceptions of Value of Orphan Drugs

    Dec 1, 2022, 00:00

  • EE157 Cost-Utility of Active Middle Ear Implants for Sensorineural Hearing Loss

    Dec 1, 2022, 00:00

  • MSR32 COVID-19 Beds’ Occupancy and Hospital Complaints: A Predictive Model

    Dec 1, 2022, 00:00

  • CO54 Dupilumab vs Placebo Improves Symptoms, Asthma Control, and Asthma-Related Quality of Life in Patients With Oral Corticosteroid-Dependent Severe Asthma Through 48 Weeks of Follow up

    Dec 1, 2022, 00:00

  • EE352 New Reimbursement Policy on Costly Treatments for Rehabilitation Care in Fran Estimated Impact in a University Hospital

    Dec 1, 2022, 00:00

  • HSD69 Cost Savings of Waste on Health by Pharmacological Inefficiencies in a Value-Based Patient Drug Safety Program

    Dec 1, 2022, 00:00

  • HTA228 Willingness to Pay for Different Severity Levels in Sweden: An Analysis of TLV Decisions (2014-2022)

    Dec 1, 2022, 00:00

  • HSD9 Comparing the Quality of the Irish Healthcare System Versus the Healthcare Systems of the Nordic Countries Using Health Outcomes Data

    Dec 1, 2022, 00:00

  • HSD111 Evaluation of the Implementation of Value-Based Healthcare With a Weekly Digital Follow-up of Lung Cancer Patients in Clinical Practice

    Dec 1, 2022, 00:00

  • EE144 APAP and Telemonitoring for Initiation and Follow-up of OSA Therapy in Germany: Economic and Environmental Evaluation

    Dec 1, 2022, 00:00

  • OP6 Quantifying the Impact of Persistent Musculoskeletal Pain on Employees at Rolls-Roy A Cross-Sectional Survey

    Dec 1, 2022, 00:00

  • HSD81 European Delphi Panel to Build Consensus on Tapering and Discontinuation of Thromboprotein-Receptor Agonists in Patients With Immune Thrombocytopenia

    Dec 1, 2022, 00:00

  • HSD54 Value-Based Healthcare (VBH): Application of Time-Driven-Activity-Based Costing (TDABC) Methodology in an Ophthalmic Clinic for Patients With Macular Degeneration (MD)

    Dec 1, 2022, 00:00

  • RWD40 Persistence and Switching Patterns of Migraine Prophylactic Medications in Canada: A Retrospective Claims Analysis Comparing Adherence and Evaluating the Economic Burden of Illness

    Dec 1, 2022, 00:00

  • HTA168 Data Maturity and Treatment Positioning to Support Reimbursement: The Case for Siltuximab (SYLVANT®) in Australia

    Dec 1, 2022, 00:00

  • PCR150 Physicians’ Perceptions of the Impact of COVID-19 on Patient Access and Adherence

    Dec 1, 2022, 00:00

  • MT30 A Systematic Review of Clinical and Economic Literature of Breast Cancer Screening with Digital Breast Tomosynthesis (DBT) Combined With Synthesised Two-Dimensional Mammography (S2D) Versus Digital Mammography Alone (DM)

    Dec 1, 2022, 00:00

  • HSD20 Real-World Treatment Patterns and Outcomes After Introduction of Immune Checkpoint Inhibitors (ICIs) in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (aNSCLC) in Europe (EU4+UK)

    Dec 1, 2022, 00:00

  • RWD28 Cervical Cancer Screening Trend and Disparity in the US, 2016 – 2020

    Dec 1, 2022, 00:00

  • PCR259 Factors Influencing Crowdfunding Donations for Patients With Dementia

    Dec 1, 2022, 00:00

  • EE81 The Budget Impact of Cangrelor for the Treatment of Patients Undergoing Percutaneous Coronary Intervention When Oral P2Y12 Inhibitors Are Not Feasible or Desirable in the UK

    Dec 1, 2022, 00:00

  • EPH172 A Longitudinal Study of Epidemiology and Treatment Management of Wilson Disease in France Based on the French National Claims Database SNDS

    Dec 1, 2022, 00:00

  • EE427 Annual Cost Savings From the Use of Empagliflozin Over DPP4I in Select Asia-Pacific Countries – Estimates Based on the Emprise East Asia Study

    Dec 1, 2022, 00:00

  • MSR49 Comparison of Methods for Identifying Genome Profiling Actionability Prognostic Factors in the Context of Small Samples Using a RWD Study

    Dec 1, 2022, 00:00

  • HTA13 How Health Technology Assessment Agencies View Clinical Evidence for Tumor Agnostic Therapies

    Dec 1, 2022, 00:00

  • EE176 Cost-Utility Analysis of Fentanyl Sublingual Formulation in the Treatment of Breakthrough Pain in Adults With Cancer, Already on Opioid Maintenance Therapy for Chronic Cancer Pain in Italy

    Dec 1, 2022, 00:00

  • PCR164 Assessment of Drug Consumption Habits, Health Behaviour, and Illness Experience of the Adult Population Among Patients With Hypertension

    Dec 1, 2022, 00:00

  • RWD68 Characteristics/Comorbidities of Vaccinated and Unvaccinated Patients With COVID-19

    Dec 1, 2022, 00:00

  • EE197 Efficacy and Economic Impact of Metformin Plus Glibenclamide Treatment During the COVID-19 Pandemic in Ecuadorian Outpatients With Type II Diabetes Mellitus

    Dec 1, 2022, 00:00

  • MSR125 Bias Adjusting for Unmeasured Confounders in Synthetic Control Analysis (SCA) Estimates of Immunotherapy Effectiveness in Advanced Non-Small Cell Lung Cancer (ANSCLC): An Output From the Q-Basel Study

    Dec 1, 2022, 00:00

  • HTA36 Value of Real-World Evidence for Treatments for Ultra Orphan or Rare Diseases: Lessons and Insights From Review of NICE Highly Specialized Technology Assessment Reports (2016-2022)

    Dec 1, 2022, 00:00

  • RWD41 Colorectal Cancer Screening Program Saved More Life Expectancy in Females and More Employment Duration in Males: Empirical Evidence From Analyzing Nationwide Data Followed for 15 Years in Taiwan

    Dec 1, 2022, 00:00

  • PCR274 One Universal Translation to Rule Them All...or Not?

    Dec 1, 2022, 00:00

  • HPR139 Analysis of Public Health Insurance Expenditures in Turkiye Between 2019-2021

    Dec 1, 2022, 00:00

  • MSR6 Data-Driven Choice Models for Moral Choice Analysis: Helpful or Harmful?

    Dec 1, 2022, 00:00

  • EE381 Cost-Effectiveness Analysis of Atrial Fibrillation Screening in the Elderly Population of Taiwan

    Dec 1, 2022, 00:00

  • EE33 Impact on Hospital Healthcare Resources, Comparison of Endoluminal Versus Surgical Treatment Strategies for Lower Limb Bypass in PAD Patients

    Dec 1, 2022, 00:00

  • SA36 Is Progression-Free Survival a Good Indicator of Overall Survival for Pazopanib in Patients With Synovial Sarcoma?

    Dec 1, 2022, 00:00

  • P60 Use Cases for Artificial Intelligence and Machine Learning Methods to Support Health Technology Assessment

    Dec 1, 2022, 00:00

  • SA30 Evaluation of National Approvals and Data Collection Durations in Retrospective Noninterventional Medical Record Review Studies Conducted in the United States (US), Canada, Europe (EU), and Asia

    Dec 1, 2022, 00:00

  • MT27 Budget Impact of a Novel Digital Therapeutic for Amblyopia From a US Private Insurer Perspective

    Dec 1, 2022, 00:00

  • EE207 Real-World Analysis of Adherence, Outcomes and Healthcare Costs of Patients Under Quadruple Combination of Antihypertensives in Italy

    Dec 1, 2022, 00:00

  • MSR106 Towards an Artificial Intelligence-Enabled Social Media Listening Solution to Inform Early Patient-Focused Drug Development Strategies

    Dec 1, 2022, 00:00

  • EE212 Budget Impact Analysis of Adopting Prophylactic Approach in the Management of Hemophilia A in Egypt From Payor Perspective

    Dec 1, 2022, 00:00

  • EE355 Budget Impact Model of a New rFVIIa (Eptacog Beta), for the On-Demand Treatment of Spontaneous Bleeding Events and Surgical Bleedings Among Hemophilia Patients with Inhibitors: A Payer Perspective From UK

    Dec 1, 2022, 00:00

  • HPR81 Evaluation of the Hungarian Generic Program Between 2010 and 2021

    Dec 1, 2022, 00:00

  • EE234 Comparing the Public Health Impact of a 15- or 20-Valent Pneumococcal Conjugate Vaccine Pediatric National Immunization Program in Spain

    Dec 1, 2022, 00:00

  • EE357 Cost-Effectiveness of Cabotegravir (CAB) + Rilpivirine (RPV) Long-Acting (LA) in People Living With HIV (PLHIV) in Austria

    Dec 1, 2022, 00:00

  • HPR171 COVID 19 Vaccination - How to Support Decisions on Vaccination Prioritization for New Variants of Concern?

    Dec 1, 2022, 00:00

  • HPR82 Price Leakage Due to International Reference Pricing: Impact of Pfizer's Not-for-Profit Pricing Initiative on Price Levels in Additional Countries

    Dec 1, 2022, 00:00

  • EE569 Axicabtagene Ciloleucel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Irish Healthcare Setting: Cost-Utility and Value of Information Analysis

    Dec 1, 2022, 00:00

  • EE530 Cost Per Response, Remission and Endoscopic Improvement of Advanced Therapies of Bio-Exposed Patients With Moderately-to-Severely Active Ulcerative Colitis (UC) in France

    Dec 1, 2022, 00:00

  • CO142 Secondary Malignancies After Radiotherapy for Prostate Cancer: A Population-Based Study

    Dec 1, 2022, 00:00

  • EE288 Economic Evaluation of Generic Tacrolimus and Innovator in Renal Transplant Recipients in Egypt

    Dec 1, 2022, 00:00

  • EE536 Patterns of Author Collaboration in Published Cost-Effectiveness Analyses

    Dec 1, 2022, 00:00

  • HTA2 Conditional Recommendations by the Canadian Agency for Drugs and Technologies in Health (CADTH)

    Dec 1, 2022, 00:00

  • EE32 Selection of Key Performance Indicators for an Economic Evaluation of Artificial Intelligence Technologies. The Case of Hosmartai (HORIZON 2020 Funded Program)

    Dec 1, 2022, 00:00

  • EPH75 Applying Machine Learning (ML) to Estimate Prevalence of Facioscapulohumeral Muscular Dystrophy (FSHD) and Related Disease Burden: Findings From United States Claims Analysis

    Dec 1, 2022, 00:00

  • RWD161 Pharmacological Treatment Disruption in Women With Post-Partum Depression (PPD) During COVID-19: A Retrospective Cohort Study Using Claim Data

    Dec 1, 2022, 00:00

  • EE560 The Impact of Molecular Tumour Board on Costs and Patient Access to Personalized Medicine

    Dec 1, 2022, 00:00

  • EE481 Cost-Effectiveness of Empagliflozin for Patients With Heart Failure Irrespective of Ejection Fraction in England

    Dec 1, 2022, 00:00

  • HTA147 Advanced Therapy Medicinal Products (ATMPS) Market Access Challenges in France

    Dec 1, 2022, 00:00

  • EE608 Cost Effectiveness Analysis of a Large (Foundation Medicine) Versus a Home-Based Medium Gene Panel for Exome Sequencing: Results of the Profiler 02 Randomized Clinical Trial

    Dec 1, 2022, 00:00

  • EE17 Economic Evaluation of Patiromer for the Treatment of Hyperkalaemia in CKD Patients With and Without HF in Italy

    Dec 1, 2022, 00:00

  • SA8 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in COPD in England: A Population-Based Study

    Dec 1, 2022, 00:00

  • RWD151 Treatment Satisfaction of Guselkumab for Plaque Psoriasis Patients in a Multi-National, Real-World Setting

    Dec 1, 2022, 00:00

  • HTA240 Indirect Comparisons of Clinical Effectiveness in NICE HTA Submissions: Software Use Trends, 2000-2022

    Dec 1, 2022, 00:00

  • EE650 Cost Effectiveness of Siponimod for Secondary Progressive Multiple Sclerosis in Turkey

    Dec 1, 2022, 00:00

  • HTA241 Rare Diseases: The Role of Managed Access

    Dec 1, 2022, 00:00

  • CO70 Investigation of Autoimmune Disease With Eosinophilic Esophagitis: A Nationwide Longitudinal Study

    Dec 1, 2022, 00:00

  • EE100 An Approach to Value-Based Pricing for Digital Health Applications in Germany

    Dec 1, 2022, 00:00

  • PCR206 Evaluation of a Multimorbidity Patient-Centered Care Model Implemented in the Chilean Public Health System: Users´ Perspective

    Dec 1, 2022, 00:00

  • EE416 Cost-Effectiveness of Pembrolizumab Monotherapy for First-Line Treatment in Adult Patients with Microsatellite Instability High/Mismatch Repair-Deficient Metastatic Colorectal Cancer From a French Perspective

    Dec 1, 2022, 00:00

  • EE85 Cost-Effectiveness Analysis of GAAD Algorithm on the Detection of Early-Stage Hepatocellular Carcinoma in Patients With Chronic Liver Disease in China

    Dec 1, 2022, 00:00

  • EE563 Evaluating the Cost-Utility of Intravesical Bacillus Calmette-Guérin Versus Radical Cystectomy in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer in the UK

    Dec 1, 2022, 00:00

  • EE161 Loss of Employment Duration and Productivity for Patients With Different Subtypes and Stages of Lung Cancer

    Dec 1, 2022, 00:00

  • EE681 Costs of Treating Acute Hereditary Angioedema (HAE) Attacks With C1 Inhibitors in Five Central and Eastern European Countries

    Dec 1, 2022, 00:00

  • EPH189 Assessing Changes in the Number and Profile of New Cases of Bacterial Sexually Transmitted Infections From 2018-2021: A Descriptive Analysis of German Claims Data

    Dec 1, 2022, 00:00

  • HTA167 Transition to New Danish HTA Process

    Dec 1, 2022, 00:00

  • HTA224 Commissioning Through Evaluation: RWE for Rituximab in the Management of Idiopathic Membranous Nephropathy

    Dec 1, 2022, 00:00

  • CO178 Cardiovascular, Neurological, and Ocular Complications of COVID-19 Among Indian Patients – A Targeted Literature Review

    Dec 1, 2022, 00:00

  • EE250 An Update of Systematic Review of Cost-Utility Studies Conducted From an Indian Perspective

    Dec 1, 2022, 00:00

  • EE470 Zanubrutinib Versus Ibrutinib to Treat Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Cost Per Responder Model From a Payer Perspective in the United States

    Dec 1, 2022, 00:00

  • EE539 Social and Economic Burden of HIV in Russia

    Dec 1, 2022, 00:00

  • HTA94 Two South African Health Technology Assessment Methods Guides: Which One Is More Suitable for the Assessment and Appraisal of Medicines?

    Dec 1, 2022, 00:00

  • EPH81 The Productivity Burden of Sleep Apnoea in Australia Over a Lifetime: A Modelling Study

    Dec 1, 2022, 00:00

  • HSD107 Recommendations for the Design and Implementation of a Multidisciplinary Consensus Guidance for Clinical Practice on Advanced Breast Cancer in Portugal

    Dec 1, 2022, 00:00

  • HTA145 Living Network Meta-Analysis for Up-to-Date Comparative Effectiveness: A Case Study in Multiple Myeloma Maintenance

    Dec 1, 2022, 00:00

  • HSD49 Improving Influenza Vaccination Rates: Evaluation of Pharmacy Vaccination Model Project During COVID-19 Pandemic in Germany

    Dec 1, 2022, 00:00

  • SA33 Demographic Characteristics of Patients Initiating Topical Combination Therapies for Plaque Psoriasis in Canada: A Claims-Based Analysis

    Dec 1, 2022, 00:00

  • EPH114 Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Gree Road to Recovery

    Dec 1, 2022, 00:00

  • PCR282 Despite the Growing Weight of Patient Voice in Medical Research, Only Few Medical Journals Allow and/or Require Plain Language Summaries (PLS)

    Dec 1, 2022, 00:00

  • EE456 Cost-Effectiveness of Tenofovir Alafenamide (TAF) for Treatment of Chronic Hepatitis B in Taiwan

    Dec 1, 2022, 00:00

  • SA2 Use of Systematic Literature Reviews (SLRs) and Meta-Analyses (MA) to Support HTA Submissions: An Application in Pancreatic Cancer

    Dec 1, 2022, 00:00

  • RWD96 The Disparity in the Utilization of Drugs for Multiple Myeloma Using Real-World Data in the US

    Dec 1, 2022, 00:00

  • HTA180 The Value-Generation-Value-Recognition Gap for Novel Gene Therapies in European HTA Systems Using X-Linked Retinitis Pigmentosa as a Case Study

    Dec 1, 2022, 00:00

  • EE660 Cost-Effectiveness of Personalized Nutrition Based on Omic Sciences in Adults With Abdominal Overweight or Obesity: A Within-Trial Analysis and Beyond-Trial Modelling in the United Kingdom and Poland

    Dec 1, 2022, 00:00

  • EE293 Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review

    Dec 1, 2022, 00:00

  • SA54 Physical and Mental Health Among Frontline Healthcare Workers During COVID-19 Pandemic in Hungary

    Dec 1, 2022, 00:00

  • Patient Heterogeneity and Equity in Stated Preference Studies

    Dec 1, 2022, 00:00

  • PCR149 Quality of Life of Patients With Chronic Wounds

    Dec 1, 2022, 00:00

  • EE371 Disease Management Costs for Patients With Intermediate-High or High-Risk Renal Cell Carcinoma (RCC) Following Nephrectomy

    Dec 1, 2022, 00:00

  • MSR22 Strategies for Effective Patient Advocacy Group Engagement in the Development and Fielding of Online Patient Burden Surveys

    Dec 1, 2022, 00:00

  • EPH4 Burden and Characteristics of COVID-19 in France During 2020 Based on National Hospital Database

    Dec 1, 2022, 00:00

  • EE219 Cost-Effectiveness Analysis of the Use of Indoscyanine Green in Patients Undergoing Laparoscopic Cholecystectomy to Avoid Biliary Tract Injuries From the Perspective of the Colombian Health System

    Dec 1, 2022, 00:00

  • MSR102 Variance-Bias Trade-Off in Covariate Adjustment in the Context of Synthetic Control Methods

    Dec 1, 2022, 00:00

  • RWD131 Investigating Resource Costs and the Experiences of Patients and Healthcare Professionals in the Treatment of Fabry Disease With Enzyme Replacement Therapy – A Multi-Country Study

    Dec 1, 2022, 00:00

  • EPH115 Medical Cost and Prevalence of Diseases Across Different Health Insurance Systems in Japan

    Dec 1, 2022, 00:00

  • EE326 Alleviating the Burden of Iron Deficiency in Heart Failure: A Multinational European Study

    Dec 1, 2022, 00:00

  • EPH82 Pharmacotherapy of Obesity in the Russian Federation: Pharmacoepidemiological Study

    Dec 1, 2022, 00:00

  • EE590 Duration and Costs of Hypoparathyroidism After Total Thyroidectomy for Thyroid Cancer: A French Nationwide Claims Database Study (1-YEAR FOLLOW-UP)

    Dec 1, 2022, 00:00

  • CO98 Influenza Vaccine and Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study in Four Tertiary-Level Hospitals in Peru

    Dec 1, 2022, 00:00

  • HTA171 Are Global Trials Good Enough to Support the Reimbursement of a New Technology in Asia? A Review of Asian HTA Submissions

    Dec 1, 2022, 00:00

  • HTA236 Early Diagnosis of Breast Cancer Saved Loss of Employment and Productivity for Women: Real World Evidence of Lifetime Impact

    Dec 1, 2022, 00:00

  • RWD134 Real-World Effectiveness of Atezolizumab Plus Bevacizumab in the Patients With Hepatocellular Carcinoma: A Multi-Institutional Cohort in Taiwan

    Dec 1, 2022, 00:00

  • PCR199 Time to First Deterioration in Health-Related Quality of Life (HRQOL) Remains the Most Common Time to Deterioration (TTD) in Non-Small Lung Cancer (NSCLC) Trials

    Dec 1, 2022, 00:00

  • EE305 Burden of Disease and Cost of Illness of Atopic Dermatitis (AD)

    Dec 1, 2022, 00:00

  • HTA109 Diagnostic Accuracy of 0.3T MRI for Knee Injuries- A Systematic Review

    Dec 1, 2022, 00:00

  • EE90 Are There Specificities for Assessing Quality of Life and Utilities in Rare Diseases for Economic Evaluation in Fran A Case Study of Published CEESP Opinions

    Dec 1, 2022, 00:00

  • EPH24 The Impact of COVID-19 Pandemic on Paediatric Vaccination Coverage Rates

    Dec 1, 2022, 00:00

  • HTA248 Could Early Scientific Advice Have Improved Outcomes in Cost-Effectiveness Markets?

    Dec 1, 2022, 00:00

  • EE77 Cost-Effectiveness Analysis of Pharmacogenetic-Guided Treatment in Drug Resistant Depression

    Dec 1, 2022, 00:00

  • SA45 Practical Considerations for Developing PICO Statements for Humanistic Burden Reviews: How to Get It Right

    Dec 1, 2022, 00:00

  • HPR42 A New Organizational Model to Manage Chronic Diseases With Digital Medicine Tools

    Dec 1, 2022, 00:00

  • EE605 Feasibility Assessment of Using MiToS Staging System for Conducting Health Economic Analysis in Amyotrophic Lateral Sclerosis (ALS)

    Dec 1, 2022, 00:00

  • RWD92 Persistence and Patterns of Exposure to Omalizumab in Patients With Asthma in France Between 2009 and 2019 (SOLAIR Study)

    Dec 1, 2022, 00:00

  • PCR1 Comparison of Infant’s CRY/Fuss Report Between Parental Perception and Recording Analysis, and Its Potential Implications on Parental Mental Health

    Dec 1, 2022, 00:00

  • EE44 Pain Therapy With Spinal Cord Stimulation (SCS) in Patients With Painful Diabetic Neuropathy (PDN): Results of a Budget Impact Model

    Dec 1, 2022, 00:00

  • EE37 Cost-Utility Analysis of Elecsys Gaad Algorithm Versus Ultrasound Plus -Fetoprotein (AFP) for HCC Surveillance in Patients With Compensated Liver Cirrhosis in the United Kingdom (UK)

    Dec 1, 2022, 00:00

  • EE156 Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure (HF) with Preserved Ejection Fraction (HFPEF) in France, Based on Emperor-Preserved Clinical Trial

    Dec 1, 2022, 00:00

  • EE392 Cost-Effectiveness Analysis of Atrial Fibrillation Screening for a 50–65-Year-Old Population With Elevated Stroke Risk

    Dec 1, 2022, 00:00

  • HSD97 Automated Versus Manual Prior Authorization for Type 2 Diabetes Mellitus Drugs: A Retrospective Study From Israel

    Dec 1, 2022, 00:00

  • EE202 Estimating the Public Health Benefits of Preventing Herpes Zoster and Postherpetic Neuralgia in Greece by Zoster Vaccines: A Modelling Study

    Dec 1, 2022, 00:00

  • PCR16 Variables Associated With Carer Quality of Life in England Using a Large, National Data Set

    Dec 1, 2022, 00:00

  • CO3 Sensitivity to Change of the Oxford Participation and Activities Questionnaire in People With Parkinson’s

    Dec 1, 2022, 00:00

  • HPR57 Do Favourable Access Conditions and Policies for Biosimilars Result in Increased Consumption in the EU4 and the UK?

    Dec 1, 2022, 00:00

  • P42 Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation

    Dec 1, 2022, 00:00

  • EE554 Costs Comparison Between Dupilumab and Omalizumab in the Treatment of Severe Allergic Asthma in the Brazilian Private Healthcare Perspective

    Dec 1, 2022, 00:00

  • PCR229 Two Simple Methods for Daily Measuring Compliance With Oral Nutritional Supplements in the Community: Electronic Self-Report Method Versus Image-Based Method

    Dec 1, 2022, 00:00

  • RWD77 Validation of Prevalence and Incidence Rates for Six Different Diseases Using Livingstone: An Online, Automated Analytical Platform

    Dec 1, 2022, 00:00

  • HSD92 Operational Savings Generated in an Integrated Care Clinic for Immune-Mediated Skin Disorders

    Dec 1, 2022, 00:00

  • EE204 Cost-Effectiveness of Everolimus Combination Therapy in Patients After Liver Transplantation Focusing on Cancer Risk: A Markov Model Using Real-World Data

    Dec 1, 2022, 00:00

  • HTA198 The Influence of the Claimed Benefit Versus the Given Benefit on the Negotiated Rebate During the German Health Technology Assessment

    Dec 1, 2022, 00:00

  • HSD63 Characteristics and Treatment Patterns of Patients Initiating Cladribine Tablets: A U.S. Commercial and Medicare Advantage Prescription Drug Claims Analysis

    Dec 1, 2022, 00:00

  • MSR109 Can Jointly Modelling PFS and OS With Mixture Cure Models Overcome Data Immaturity Problems?

    Dec 1, 2022, 00:00

  • PCR258 Citizens’ Preferences for Robot-Assisted Hip Replacement: Results of an Online Cross-Sectional Study in Hungary

    Dec 1, 2022, 00:00

  • HTA162 Assessing Literature Reviews in NICE Single and Multiple Technology Appraisals

    Dec 1, 2022, 00:00

  • EE73 The Challenge of Demonstrating Cost Effectiveness in Alzheimer's Disease in England: Case Study of a Hypothetical Emerging Treatment

    Dec 1, 2022, 00:00

  • CO13 Evidence Gap Analysis of the Burden of Illness and Treatment of Primary Immune Thrombocytopenia

    Dec 1, 2022, 00:00

  • HPR12 Treatment Inequities Among Cancer Patients Due to Reimbursement: From the Perspective of 130 Medical Oncologists

    Dec 1, 2022, 00:00

  • EE259 US Reference Pricing Impact on Transparency, Pricing, and Access in the EU4 Final

    Dec 1, 2022, 00:00

  • EE312 Are Methods Used to Generate Utility Values Adequately Included in Technology Assessments for Children and Adolescents? Lessons From HAS Assessments of Manufacturers’ Cost-Utility Analyses

    Dec 1, 2022, 00:00

  • EE256 Budget Impact Analysis of the Introduction of a Novel Gene Expression Biomarker Test for Early-Stage Breast Cancer Patients in Cyprus

    Dec 1, 2022, 00:00

  • EPH141 Dispensing Patterns for Rabies in Humans: A South African Database Analysis

    Dec 1, 2022, 00:00

  • HTA69 Delay of Innovative Oncology Treatments - Case From Bulgaria

    Dec 1, 2022, 00:00

  • HPR145 Factors of Access to the Market of Innovative Specialties in Algeria: The Case of Hospital Drugs

    Dec 1, 2022, 00:00

  • HSD28 Most Common Treatments in Patients With Treatment Resistant Depression Based on European Cohort Study Real-World Evidence

    Dec 1, 2022, 00:00

  • PCR77 Factors to Consider in Deciding on B/Ts Dmards to Manage Inflammatory Arthritis From a Patient Perspective: A Systematic Review

    Dec 1, 2022, 00:00

  • RWD147 Demonstrating the Application of Real-World Evidence for Health Technology Assessment Using a Federated Data Network

    Dec 1, 2022, 00:00

  • RWD133 Assessing the Impact of Bisphosphonates and Selective Estrogen Receptor Modulators in Post-Menopausal Osteoporosis

    Dec 1, 2022, 00:00

  • HTA58 Does NICE’s STA Process Effectively Reward the Value of Double-Branded Oncology Combinations, When Compared to Oncology Monotherapies?

    Dec 1, 2022, 00:00

  • HTA204 HTA Assessment of Adaptive Trials for Oncology Drugs in Europe

    Dec 1, 2022, 00:00

  • SA80 Data Extraction Templates in Systematic Literature Reviews: How Systematic Are We?

    Dec 1, 2022, 00:00

  • CO127 Empirical vs Documented Use of Ceftolozane-Tazobactam for the Treatment of Complicated Infections in French Hospital Settings

    Dec 1, 2022, 00:00

  • EE451 A Narrative Review of The Economic Burden Attributable to Obesity and Overweight in China

    Dec 1, 2022, 00:00

  • HSD18 Access to Healthcare Services During COVID-19 Restrictions in Kazakhstan: A Nationwide Survey on COVID-19 and Lifestyle Changes

    Dec 1, 2022, 00:00

  • CO82 The Assessment of Surrogate Endpoints and Their Impact on HTA Recommendations

    Dec 1, 2022, 00:00

  • HPR123 CEE: Brief Overview of Orphan Drug Reimbursement and Selected Clinical Characteristics

    Dec 1, 2022, 00:00
  • «
  • 31
  • 32
  • 33
  • 34
  • 35 (current)
  • 36
  • 37
  • 38
  • 39
  • 40
  • »